Product Certification&
    Enterprise Certification

  • Mr.Xie
    Tel: +86-592-5853819

  • Ms.Serein Yan
    Region Sales Manager
    Tel: +86 0592 5887162

  • Ms.Coco Lv
    Region Sales Manager
    Tel: 0086-592-5881075

  • Ms.Penny Pan
    Region Sales Manager
    Tel: 0086-592-5881087

  • Ms.Shirley Shi
    Region Sales Manager
    Tel: +8613666090822

  • Ms.Denise Lai
    Region Sales Manager
    Tel: 0086-592-5887167

  • Mr.Duncan Deng
    Region Sales Manager
    Tel: +8617750663255

  • Ms.Susie Yan
    Region Sales Manager
    Tel: +8618060975837

  • Ms.Annette Wang
    Region Sales Manager
    Tel: +8615882299465

  • Mobile:+86 13806035118
  • Tel:+86-592-5853819
  • Fax:+86-592-5854960
  • URL:http://www.china-sinoway.com
  • Province/state:fujian
  • City:Xiamen
  • Street:16/F,Huicheng Comm,Complex,No839 XiaHe Rd, Xiamen,China
  • MaxCard:
Home > Products >  98% up USP standard GMP certified DMF documents API Atorvastatin Calcium 134523-03-8

98% up USP standard GMP certified DMF documents API Atorvastatin Calcium 134523-03-8 CAS NO.134523-03-8

  • Min.Order: 1 Kilogram
  • Payment Terms: L/C,D/A,D/P,T/T
  • Product Details

Keywords

  • Atorvastatin Calcium
  • Atorvastatin
  • Atorvastatin Calcium 134523-03-8

Quick Details

  • ProName: 98% up USP standard GMP certified DMF ...
  • CasNo: 134523-03-8
  • Molecular Formula: C66H68CaF2N4O10
  • Appearance: White or almost white hygroscopic powd...
  • Application: Treat the hypertension
  • DeliveryTime: 7 working days
  • PackAge: 25kg per drum
  • Port: shanghai/beijing/hangzhou
  • ProductionCapacity: 1000 Kilogram/Month
  • Purity: 98%
  • Storage: Normal temperature
  • Transportation: normal temperature.
  • LimitNum: 1 Kilogram

Superiority

Why is SINOWAY:

1) Specialized in pharmaceutical and healthcare industrial for 34 years.

2) ISO 9001:2015 & SGS audited supplier . 

3) Accept various payment terms : T.T 30-60 days.

4) We have warehouse in USA with quickly shipment .

5) We can do different terms of FOB ,CIF/CIP ,DDP ...

 

Details

Product name

Atorvastatin calcium

CAS No.

134523-03-8

Molecular Formula

C66H68CaF2N4O10

Molecular Weight

1155.36

Quality Standard

98% up by HPLC

Appearance

White or almost white powder

ITEMS

SPECIFICATION

RESULT

Appearance

White or almost white powder

Conforms

Identification

IR Calcium

Conforms

Water

3.5%-5.5%

5.0%

Heavy metals

 20 ppm

< 20 ppm

Assay

98.0%-102.0% (calculated to anhydrous substances)

99.5%

Enantiomer atorvstatin calcium E

 0.3%

0.05%

 

 

 

Related substances

Impurity A:  0.2%

Impurity B:  0.3%

Impurity C:  0.3%

Impurity D:  0.1%

Unspecified impurity:  0.1%

Total:  1.0 %

0.1%

0.04%

0.04%

0.07%

0.1%

0.5%

Residual solvents

Ethanol: 5000ppm

Tothene: 890ppm

N-Hexane: 290ppm

ND

158ppm

ND

Bioburden

(By HPLC)

Total Aerobic microbial count  1000CFU/g

Total combined mold and yeast count  100CFU/g

Eschericha coli: Negative

< 10 CFU/g

< 80CFU/g

ND

Conclusion

The result conforms with USP34

 

Application of Atorvastatin calcium

1. Hypercholesterolemia

patients with primary hypercholesterolemia. Including patients with familial hypercholesterolemia (heterozygous type) or mixed hyperlipidemia (equivalent to types IIa and IIb of Fredrickson classification), if the effect of dietary therapy and other non-drug treatments is not satisfactory, the application of this product can be treated It has elevated total cholesterol (TC), elevated low-density lipoprotein cholesterol (LDL-C), elevated apolipoprotein B (Apo B), and elevated triglycerides (TG).

In patients with homozygous familial hypercholesterolemia, atorvastatin can be used in combination with other lipid-lowering therapy (eg, LDL plasma dialysis) or alone (when no other therapy is available) to lower TC and LDL-C.

 

2. coronary heart disease

For patients with coronary heart disease or coronary heart disease equivalent risk disease (such as diabetes, symptomatic atherosclerotic disease, etc.) combined with hypercholesterolemia or mixed dyslipidemia, this product is suitable for: reducing the risk of non-fatal myocardial infarction, reducing Risk of fatal and non-fatal stroke, reduced risk of revascularization, reduced risk of hospitalization for congestive heart failure, and reduced risk of angina.

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog